5 Stocks to Watch: Week of 3/24/2025

Even in a mixed-up market, there’s always something worth watching — this week, we’ve got an eclectic mix of Strong Buy recommendations, courtesy of our Strong Buy Stocks from Top Wall Street Analysts screener:

• Marvell Technology Inc (NASDAQ: MRVL) enjoys 18 Strong Buy ratings — here’s the latest one 
• Gilead Sciences Inc (NASDAQ: GILD) continues to perform well (and this trajectory could continue)
• Amneal Pharmaceuticals (NASDAQ: AMRX) is slowly but surely gaining market share
• Learn why US Foods Holding (NYSE: USFD) earns the esteemed title of “Stock of the Week”
• JD.com (NASDAQ: JD) is currently surging. Keep reading to find out why (and why it could continue)

1. Marvell Technology Inc (NASDAQ: MRVL)

A quiet powerhouse in the semiconductor space, Marvell Technology has carved out a dominant position in data infrastructure, AI, and cloud computing. The company’s latest earnings call, although most metrics came in at or above estimates, disappointed investors, although Wall Street remains confident regarding long-term growth prospects — so MRVL stock may be available at a pretty significant discount.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $69.81  — get current quote > 

Max 1-year forecast: $150.00 

Why we’re watching:

• A whopping 23 analysts issue ratings for MRVL shares. A vast majority — 18, to be exact, have given it a Strong Buy rating, while the remaining ratings are divided between 4 Buys and 1 Hold. See the ratings
• The average 12-month price forecast for Marvell Technology stock implies a 76.26% upside.
• Stifel Nicolaus researcher Tore Svanberg (a top 6% rated analyst) reiterated an earlier Strong Buy rating following the company’s Q4 and FY 2025 earnings call. The analyst cut his price target from $130 to $115.
• Svanberg said the adjustment was "entirely on lower comps." Looking ahead, custom ASIC is seeing further momentum, the analyst said, with two programs in high-volume production at two lead hyperscalers and a third hyperscaler on track for a ramp in CY 2026.
• Many of the same sentiments were echoed by Citigroup’s Atif Malik (a top 1% rated analyst), who slashed his price target on MRVL stock from $136 to $122 while keeping a Strong Buy rating. 
• Looking ahead, Malik told readers that Citigroup still believes Marvell Technology will take advantage of the "robust" AI investment macro to swiftly scale its application-specific integrated circuit business.  
• Marvell Technology stock has an overall Zen Rating of B, and currently ranks in the top 7% of equities according to the 115 factors our system takes into account.
• Looking at MRVL’s Component Grade ratings, one instantly jumps off the page — Growth. In this category, the stock ranks in the 99th percentile. (See all 7 Zen Component Grades here >)

2. Gilead Sciences Inc (NASDAQ: GILD)

Gilead Sciences operates in the dynamic world of biotech. In recent years, it has increasingly shifted its focus to oncology and cell therapy. With the market in the middle of a downturn, defensive plays have begun to receive more attention from investors — and Gilead Sciences is in a great position to benefit from the shift.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $107.51  — get current quote > 

Max 1-year forecast: $140.00

Why we’re watching:

• At present, 21 analysts offer ratings and price targets for GILD stock. The ratings are evenly split between 7 Strong Buys, 7 Buys, and 7 Holds. See the ratings 
• Matthew Harrison of Morgan Stanley (a top 23% rated analyst) maintained a Strong Buy rating on Gilead Sciences stock on March 11 and raised his 12-month price forecast from $123 to $130.
• Harrison said they hiked their price target on Gilead Sciences after Morgan Stanley raised its Livdelzi estimates on recently completed physician checks indicating a "strong early launch" for the oral prescription medicine.
• GILD carries an overall Zen Rating of A — and stocks in this category have provided an average annual return of 32.52% since the early 2000s.
• Moreover, Gilead Sciences stock actually ranks in the top 1% of the equities we track.
• The stock’s Sentiment Component Grade rating, which measures analyst revisions, earnings surprises, short interest, and insider selling, is an A — and in this category, GILD ranks in the top 3% of the stocks our system keeps track of.
• We’d be remiss not to mention GILD’s Value and Financials ratings — as it is in the 94th and 93rd percentile, respectively, in these categories. (See all 7 Zen Component Grades here >)

3. US Foods Holding (NYSE: USFD)

Food — whether you’re peckish or famished, gluten-free, pescatarian, or anything in between, we all need it. You might “need” to add USFD to your stock portfolio as well. Well, need might be a strong word — but once you see why our Editor-in-Chief selected US Foods Holding ahead of any other stock this week, we have little doubt that you’ll want to include it in your holdings. Not to spoil the surprise, but this defensive pick has provided quite outsized returns in the past couple of years.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $65.07   — get current quote > 

Max 1-year forecast: $85.00

Why we’re watching:

• USFD is our Stock of the Week. Our Zen Investor Editor-in-Chief, Steve Reitmeister, did a deep dive on US Foods Holding in a Monday article. We highly suggest you take a look at the article — but here are a couple of highlights.
• USFD is in the 93.49 percentile of all stocks we analyze...but only those 95.00 and above are A.
• Steve referred to the stock as the most conservative holding in his Zen Investor portfolio. However, on top of a top 2% reading for Safety, USFD also ranks highly in terms of Value, Momentum, Financials, and Growth.
• Over the past 5 years, the company’s earnings have doubled — while share prices have quadrupled.
• Wall Street seems to be on board — Mark Carden of UBS (a top 19% rated analyst) recently maintained a Strong Buy rating on the stock, while also increasing his price target from $77 to $83.
• Barclays researcher Jeffrey Bernstein (a top 13% analyst) concurs — having doubled down on a previous Strong Buy rating while raising his 12-month price forecast for USFD from $82 to a Street-high $85.
• As we’ve mentioned, Us Food Holding stock just barely misses the mark to qualify for an overall Zen Rating of A — but if things keep going the way they are, this “defensive” pick could soon qualify for the highest grade. (See all 7 Zen Component Grades here >)

4. JD.com (NASDAQ: JD)

One of the titans of e-commerce in China, JD.com is the country’s largest retailer by revenue. Despite a 55.89% surge over the past year, the stock remains undervalued — and analysts estimate that plenty of further growth is to come in 2025. With a recent earnings beat and a substantial share buyback program at play, JD stock is worth a closer look — particularly for investors eager to diversify.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $44.83  — get current quote > 

Max 1-year forecast: $58.00 

Why we’re watching:

• A consensus Strong Buy, JD.com currently has 5 Strong Buy ratings and 2 Buy ratings — with not a single Hold, Sell, or Strong Sell rating. See the ratings
• Barclays’ Gregory Zhao (a top 21% rated analyst) maintained a Strong Buy rating and increased his price target for JD.com stock from $50 to $55 ahead of the company’s Q4 and FY 2024 earnings call.
• In a note shared with investors, Zhao attributed the hike to China’s $41 billion consumption stimulus.
• Following the quarterly report, which saw both EPS and revenues beat estimates, Fawne Jiang of Benchmark (a top 6% rated analyst) also doubled down on an earlier Strong Buy rating, and upped their price target from $47 to a Street-high $58, a figure that implies a 42.72% upside.
• The analyst pointed out that management offered "upbeat" FY 2025 guidance, expecting revenue and net profit to expand by high single digits instead of the mid-single digits predicted by the Street.
• With an overall Zen Rating of A, JD stock belongs to a class of equities that have delivered an average annual return of 32.52% since the turn of the millennium.
• At present, JD.com stock ranks in the top 4% and top 9% in terms of its Growth Component Grade rating and Value Component Grade rating, respectively. (See all 7 Zen Component Grades here >)

5. Amneal Pharmaceuticals (NASDAQ: AMRX)

Amneal Pharmaceuticals has quietly become a major force in the generic and specialty pharmaceutical markets, leveraging its deep pipeline and expanding biosimilars portfolio. While its generics business provides steady cash flow, the company’s real growth catalyst lies in its specialty segment, with a focus on neurology and endocrinology treatments.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $8.73 — get current quote > 

Max 1-year forecast: $12.00 

Why we’re watching:

• To keep it short and simple — 4 analysts cover AMRX stock, and all 4 give it a Strong Buy rating, with an average 12-month price forecast that implies a 32.18% upside. See the ratings
• JP Morgan’s Chris Schott (a top 19% rated analyst) recently upgraded the stock to a Strong Buy and raised his price target from $9 to a Street-high $12.
• Schott attributed their upgrade and price target hike to "the ahead-of-expectations start to the Crexont launch and continued momentum elsewhere across the company's portfolio."
• Looking ahead, the analyst said that JPMorgan believes Amneal Pharmaceuticals' generics business is increasingly well positioned, with a portfolio more levered towards complex products and biosimilars. The company's portfolio should support sustainable high-single-digit growth over the next several years, Schott detailed.
• With a Zen Rating of A, AMRX has been identified as having a high likelihood of outperforming the wider market going forward.
• Amneal Pharmaceuticals shines when it comes to its Growth Component Grade rating — where it ranks in the top 5% of stocks. (See all 7 Zen Component Grades here >)

What to Do Next?

• 8 Stock Lists You Need Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return > 
• 4 Step Process to Find More 100%+ Stock Winners >

Want to get in touch? Email us at news@wallstreetzen.com.